Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label Phase IIIb Study of Regorafenib in Metastatic Colorectal Cancer After Standard Therapy
2011-005836-25Phase 3Completed
- Sponsor
- Bayer
- Start
- Feb 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of regorafenib in metastatic colon cancer (mCRC), sponsored by Bayer. Primary endpoint: Safety of regorafenib. Started Feb 2012; status: completed.
02
Drugs
regorafenib
03
Conditions
metastatic colon cancer (mCRC)
Beyond the preview
Go deeper on 2011-005836-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-005836-25.